Preparing Serine-Free Medium
The Two Problems
| Problem | Mechanism | Consequence |
|---|---|---|
| Substitution changes composition | Removing an amino acid removes its mass and charge | Osmolarity falls; sodium or chloride may shift |
| Serum reintroduces the nutrient | Serum contains serine and glycine at hundreds of micromolar | Medium is not serine-free |
Important distinction. A commercial "serine-free" formulation may exist, but most laboratories make the medium by omitting the amino acid from a custom powder or by using a dropout kit. In both cases the substitution used to maintain osmolarity must be stated, because an isosmotic replacement (typically glycine or sodium chloride) is itself a variable.
Part 1 — Making the Medium
| Step | Detail | Why |
|---|---|---|
| Base formulation | Custom powder without serine, or a dropout kit | Consistency between batches |
| Osmotic replacement | Equimolar glycine, or NaCl, or sucrose | Document which, and use the same one throughout |
| Glycine decision | Remove together, or keep | Determines whether serine or glycine is limiting |
| Serum | Dialysed, or define the contribution | Serum serine is not negligible |
| pH | Adjust after additions | Dropout media often drift |
| Filtration | Sterile filter after complete dissolution | Precipitation of divalent salts |
| Verification | LC-MS or a serine-responsive readout | Confirms what was made |
The seventh step is the one that distinguishes a controlled experiment from an assumed one. A single LC-MS injection of the prepared medium, with a serine standard curve, takes an hour and settles the question of whether serine is present.
Part 2 — Serum and the Illusion of Deprivation
| Serum fraction | Serine content | Mitigation |
|---|---|---|
| Undialysed FBS | Hundreds of micromolar | Not compatible with deprivation |
| Dialysed FBS (10 kDa) | Low but not zero | Verify by LC-MS |
| Serum-free, defined | Zero by formulation | Requires a validated supplement |
| Low-serum (1–2%) | Reduced but variable | Not a substitute for dialysis |
Caveat on dialysis. Dialysis removes small molecules, but the residual concentration depends on the membrane cut-off, the ratio of serum to buffer, and the number of exchanges. A "dialysed serum" that still contains 50 µM serine is adequate for some experiments and useless for a PHGDH dependency study. Measured, not assumed.
Part 3 — What the Experiment Can Support
| Claim | Requires | Not sufficient |
|---|---|---|
| "Cells require serine synthesis" | Serine-free, dialysed serum, PHGDH loss, serine rescue | Growth difference in standard medium |
| "Glycine is limiting" | Serine-free but glycine-replete arms | Removing both |
| "One-carbon supply is limiting" | Formate or nucleoside rescue | Serine rescue alone |
| "The dependency is specific to serine" | Glycine and formate arms without rescue | A single dropout condition |
Readout note. The rescue panel — serine, glycine, formate, nucleosides, and a methyl donor — is what converts a deprivation phenotype into a statement about which product was limiting. Without it, "serine dependency" means only that removing serine slowed growth.
Part 4 — Model Requirements and Recurring Failures
| Requirement | Why |
|---|---|
| Osmotic replacement stated | It is a variable |
| Serum dialysis documented and verified | Otherwise the medium is not free |
| Glycine handled deliberately | It is interconvertible with serine |
| Duration of deprivation matched to the readout | Adaptation occurs within a day |
| Proliferation measured | Serine demand follows biomass |
| Rescue panel included | Identifies the limiting product |
Recurring failures:
- • Medium called serine-free without verification.
- • Osmolarity not matched, so the phenotype is partly osmotic.
- • Glycine removed at the same time, confounding the interpretation.
- • Undialysed serum used, which supplies the amino acid.
- • Deprivation too short or too long, capturing adaptation or death rather than dependency.
- • No rescue panel, leaving the mechanism unassigned.
- • Batch-to-batch variation in custom powder not documented.
Part 5 — A Practical Sequence
- Verify the base medium's serine and glycine content by LC-MS.
- Prepare the dropout medium with a stated osmotic replacement.
- Dialyse serum and verify the residual serine.
- Test growth over 72 hours with a serine dose–response (0, 10, 30, 100, 400 µM).
- In the serine-free condition, run the rescue panel.
- Only then introduce the genetic perturbation.
The fourth step is what makes the experiment quantitative: a dose–response identifies the concentration at which the dependency appears, which is more informative than a single zero-serine arm.
If you need dropout media with verified composition and osmolarity matching, we can scope the protocol with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Serum contribution, cellular serine synthesis capacity and adaptation times vary by cell type and formulation. Verification is required for each medium batch.
Growth in a dropout medium does not establish which nutrient was limiting, and a rescue with serine does not establish that serine synthesis was the required function.
Scientific interpretation and experimental design
- • A dropout changes osmolarity. Replace and state it.
- • Serum contains serine. Dialyse and verify.
- • Glycine is not neutral. Decide deliberately.
- • Verify the medium. One LC-MS run.
- • Dose–response beats zero. It locates the threshold.
- • Rescue panel assigns the mechanism.
Selected references for further reading
- • Maddocks OD, et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2013;493:542–546.
- • Labuschagne CF, et al. Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Reports. 2014;7:1248–1258.
- • Yang L, et al. Serine and one-carbon metabolism in cancer. Nature Reviews Cancer. 2016;16:650–662.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »